Myriad's Impact on Nanotechnology? Nanotechnology's Impact on Myriad??

16 March 2013 Cleantech & Nano Publication
On April 15, 2013, the Supreme Court will hear oral arguments in the Myriad Genetics v. Association for Molecular Pathology litigation. The patent world is watching, particularly those who focus on emerging technologies. On March 14, 2013, the NanoBusiness Commercialization Association filed a brief  in support of Myriad Genetics (brief prepared by Foley & Lardner, LLP). In addition to arguing that the patent claims should be patent eligible, which is the essence of the case, the brief also argues that patents do not preempt others from experimenting on, improving upon, or designing around a patented invention. With today being the first day of the new first-to-file regime, patent lawyers of all stripes are busy these days keeping up with dramatic changes to the patent system. The Supreme Court could use the Myriad case to establish a new paradigm for patent eligibility. Stay tuned.

Related Services


Foley Weekly Automotive Report
03 August 2021
Dashboard Insights
Podcast Episode 57: Kristel Schorr, Partner
03 August 2021
Foley Career Perspectives
New Facebook Policy Requires Certification and Pre-Approval for Telemedicine Company Advertisements
03 August 2021
Health Care Law Today
Act Now: Employer Obligations Under New York HERO Act
02 August 2021
Labor & Employment Law Perspectives
30th Annual Law of Product Distribution & Franchise Seminar
29 September | 7 & 20 October 2021
Milwaukee | Chicago | Dallas
7th National Telehealth Summit
4-5 October 2021
Miami Beach, FL
AHLA Fraud & Compliance Forum
21-22 September 2021
Baltimore, MD
2nd Clinical Trial Agreements Forum
16-17 September 2021
Online Livestream